159 related articles for article (PubMed ID: 20371725)
1. Interstitial infusion of glioma-targeted recombinant immunotoxin 8H9scFv-PE38.
Luther N; Cheung NK; Souliopoulos EP; Karampelas I; Bassiri D; Edgar MA; Guo HF; Pastan I; Gutin PH; Souweidane MM
Mol Cancer Ther; 2010 Apr; 9(4):1039-46. PubMed ID: 20371725
[TBL] [Abstract][Full Text] [Related]
2. Intraparenchymal and intratumoral interstitial infusion of anti-glioma monoclonal antibody 8H9.
Luther N; Cheung NK; Dunkel IJ; Fraser JF; Edgar MA; Gutin PH; Souweidane MM
Neurosurgery; 2008 Dec; 63(6):1166-74; discussion 1174. PubMed ID: 19057330
[TBL] [Abstract][Full Text] [Related]
3. Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin.
Kioi M; Seetharam S; Puri RK
Mol Cancer Ther; 2008 Jun; 7(6):1579-87. PubMed ID: 18566228
[TBL] [Abstract][Full Text] [Related]
4. Transforming growth factor-alpha-Pseudomonas exotoxin fusion protein (TGF-alpha-PE38) treatment of subcutaneous and intracranial human glioma and medulloblastoma xenografts in athymic mice.
Phillips PC; Levow C; Catterall M; Colvin OM; Pastan I; Brem H
Cancer Res; 1994 Feb; 54(4):1008-15. PubMed ID: 8313355
[TBL] [Abstract][Full Text] [Related]
5. Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies.
Kunwar S
Acta Neurochir Suppl; 2003; 88():105-11. PubMed ID: 14531568
[TBL] [Abstract][Full Text] [Related]
6. Investigation of a plasmid containing a novel immunotoxin VEGF165-PE38 gene for antiangiogenic therapy in a malignant glioma model.
Hu CC; Ji HM; Chen SL; Zhang HW; Wang BQ; Zhou LY; Zhang ZP; Sun XL; Chen ZZ; Cai YQ; Qin LS; Lu L; Jiang XD; Xu RX; Ke YQ
Int J Cancer; 2010 Nov; 127(9):2222-9. PubMed ID: 20127864
[TBL] [Abstract][Full Text] [Related]
7. Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas.
Kuan CT; Wakiya K; Keir ST; Li J; Herndon JE; Pastan I; Bigner DD
Int J Cancer; 2011 Jul; 129(1):111-21. PubMed ID: 20824708
[TBL] [Abstract][Full Text] [Related]
8. A novel bispecific immunotoxin delivered by human bone marrow-derived mesenchymal stem cells to target blood vessels and vasculogenic mimicry of malignant gliomas.
Zhang Y; Sun X; Huang M; Ke Y; Wang J; Liu X
Drug Des Devel Ther; 2015; 9():2947-59. PubMed ID: 26089644
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice.
Laske DW; Ilercil O; Akbasak A; Youle RJ; Oldfield EH
J Neurosurg; 1994 Mar; 80(3):520-6. PubMed ID: 8113865
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro.
Hassan R; Lerner MR; Benbrook D; Lightfoot SA; Brackett DJ; Wang QC; Pastan I
Clin Cancer Res; 2002 Nov; 8(11):3520-6. PubMed ID: 12429643
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.
Kreitman RJ; Margulies I; Stetler-Stevenson M; Wang QC; FitzGerald DJ; Pastan I
Clin Cancer Res; 2000 Apr; 6(4):1476-87. PubMed ID: 10778980
[TBL] [Abstract][Full Text] [Related]
12. Molecular targeting of malignant glioma cells with an EphA2-specific immunotoxin delivered by human bone marrow-derived mesenchymal stem cells.
Sun XL; Xu ZM; Ke YQ; Hu CC; Wang SY; Ling GQ; Yan ZJ; Liu YJ; Song ZH; Jiang XD; Xu RX
Cancer Lett; 2011 Dec; 312(2):168-77. PubMed ID: 21924825
[TBL] [Abstract][Full Text] [Related]
13. Anti-HIV-1 immunotoxin 3B3(Fv)-PE38: enhanced potency against clinical isolates in human PBMCs and macrophages, and negligible hepatotoxicity in macaques.
Kennedy PE; Bera TK; Wang QC; Gallo M; Wagner W; Lewis MG; Berger EA; Pastan I
J Leukoc Biol; 2006 Nov; 80(5):1175-82. PubMed ID: 16923920
[TBL] [Abstract][Full Text] [Related]
14. Convection-enhanced delivery in clinical trials.
Hall WA; Rustamzadeh E; Asher AL
Neurosurg Focus; 2003 Feb; 14(2):e2. PubMed ID: 15727423
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma.
Rand RW; Kreitman RJ; Patronas N; Varricchio F; Pastan I; Puri RK
Clin Cancer Res; 2000 Jun; 6(6):2157-65. PubMed ID: 10873064
[TBL] [Abstract][Full Text] [Related]
16. A new design immunotoxin for killing high-grade glioma U87 cells: from in vitro to in vivo.
Luqiu Z; Yiquan K; Gengqiang L; Yijing L; Xiaodan J; Yingqian C
J Immunotoxicol; 2012; 9(4):353-8. PubMed ID: 22458328
[TBL] [Abstract][Full Text] [Related]
17. Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors.
Mansfield E; Amlot P; Pastan I; FitzGerald DJ
Blood; 1997 Sep; 90(5):2020-6. PubMed ID: 9292538
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial.
Wayne AS; Kreitman RJ; Findley HW; Lew G; Delbrook C; Steinberg SM; Stetler-Stevenson M; Fitzgerald DJ; Pastan I
Clin Cancer Res; 2010 Mar; 16(6):1894-903. PubMed ID: 20215554
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas.
Li Q; Verschraegen CF; Mendoza J; Hassan R
Anticancer Res; 2004; 24(3a):1327-35. PubMed ID: 15274292
[TBL] [Abstract][Full Text] [Related]
20. Combined effects of radiation and interleukin-13 receptor-targeted cytotoxin on glioblastoma cell lines.
Kawakami K; Kawakami M; Liu Q; Puri RK
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):230-7. PubMed ID: 16111594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
